The performance of TTE is associated with a 28-day
mortality beneft in a general population of septic, critically
ill patients. The mechanism of this beneft remains
to be explored but may be related to the increased use of
fuids and vasoactive agents as indicated and guided by
TTE results. Given that for most of ICU practice, randomized
controlled trial (RCT)-based data are lacking and
no RCT will likely be performed to provide evidence in
the future, the application of the real-world data that is
captured in EHRs is necessary to assess the clinical efectiveness
of interventions such as TTE. While these investigations
must be performed with full awareness of and
attention to the complexity, and possible confounding by
indication, of such data applications, they are now quite
feasible and, we feel, absolutely necessary in the future
development and evolution of optimal clinical care.
Transthoracic echocardiographyand mortality in sepsis: analysis of the MIMIC-IIIdatabase
Mengling Feng1
, Jakob I. McSparron2*, Dang Trung Kien1
, David J. Stone3
, David H. Roberts4
,
Richard M. Schwartzstein4
, Antoine Vieillard‑Baron5
and Leo Anthony Celi4,6
© 2018 Springer-Verlag GmbH Germany, part of Springer Nature and ESICM
No comments:
Post a Comment